International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older

Arcutis Press Release Graphic

The United States Food and Drug Administration (FDA) announced on July 29 the approval of Arcutis’ ZORYVE™ (Roflumilast) cream 0.3% for the treatment of plaque psoriasis in individuals 12 years of age or older. ZORYVE is a once-daily, steroid-free cream approved to treat mild, moderate, and severe plaque psoriasis. ZORYVE™ has proven to provide patients with rapid clearance of plaques and reduction in itch in all affected areas of the body. This is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.

arcutis

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Tags

Recent Posts

Bachelez - New President Announcement

IPC Appoints New President for 2023

Think Tank Congress

Focus on Psoriasis: A Report from the 2022 IPC Think Tank – Miami

IPC Volunteer of the year 2022

Meet Our 2022 Volunteers of the Year

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.